Seeing Is Believing
Currently out of the existing stock ratings of Joseph Munda, 13 are a BUY (61.9%), 8 are a HOLD (38.1%).
Analyst Joseph Munda, currently employed at FIRST ANALYSIS, carries an average stock price target met ratio of 97.22% that have a potential upside of 20.26% achieved within 510 days.
Joseph Munda’s has documented 45 price targets and ratings displayed on 7 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on NEO, NeoGenomics at 28-Feb-2020.
Analyst best performing recommendations are on ANIK (ANIKA THERAPEUTICS).
The best stock recommendation documented was for NEO (NEOGENOMICS) at 10/24/2018. The price target of $18 was fulfilled within 7 days with a profit of $3.7 (25.87%) receiving and performance score of 36.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$15
$4.99 (49.85%)
$15
1 months 10 days ago
(22-Sep-2025)
10/19 (52.63%)
$5.88 (64.47%)
110
Buy
$32
$21.99 (219.68%)
$61
2 years 2 months 24 days ago
(08-Aug-2023)
1/3 (33.33%)
$11.99 (59.92%)
73
Hold
$35
3 years 18 days ago
(14-Oct-2022)
0/2 (0%)
$8.78 (33.49%)
Hold
$46
$35.99 (359.54%)
$46
3 years 11 months 15 days ago
(17-Nov-2021)
0/2 (0%)
$5.44 (13.41%)
Buy
$65
$54.99 (549.35%)
$54
5 years 9 months 23 days ago
(09-Jan-2020)
5/6 (83.33%)
$15.2 (30.52%)
21
What Year was the first public recommendation made by Joseph Munda?